secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062007
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports Q3 net loss $10.3M ($0.35/sh); cash $59.6M; advances tegoprubart trials
--------------------------------------------------------------------------------

- Net loss of $10.3M ($0.35 per share) vs $10.5M ($0.73) YoY; R&D spend $7.9M.
- Cash & short-term investments $59.6M as of Sept 30, 2023, up from $56.4M at Dec 31, 2022.
- Phase 1b data: tegoprubart prevented kidney transplant rejection; mean eGFR >70 at all post-Day 90 timepoints.
- First participant dosed in Phase 2 BESTOW trial for kidney transplant rejection; enrollment completion targeted end of 2024.
- Tegoprubart used in second-ever pig-to-human heart transplant; appointed new CMO (Eliezer Katz) and two board members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023062007/0000950170-23-062007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023062007/eldn-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer